AcquisitionsJun 4, 2026, 08:02 AM
SciSparc's NeuroThera Labs Acquires 54% of CliniQuantum
AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., completed the acquisition of approximately 54% interest in CliniQuantum Ltd., a private Israeli technology company. The acquisition involved the issuance of 56,600,000 common shares of NeuroThera, valued at approximately CAD$9.46 million, with potential earn-out payments of up to US$2.5 million contingent on milestones. CliniQuantum specializes in applying quantum simulation to clinical trial data analysis.
Key Highlights
- NeuroThera Labs acquired approximately 54% interest in CliniQuantum Ltd.
- Consideration included 56,600,000 common shares of NeuroThera.
- The share consideration was valued at approximately CAD$9,459,954.20.
- Potential earn-out payments up to US$2,500,000 are contingent on milestones.
- CliniQuantum develops a platform for quantum simulation in clinical trial data analysis.
- CliniQuantum holds an exclusive license for a US provisional patent application.
- SPA amendment set a minimum share price of CAD$0.05 for earn-out payments.
Price Impact
More from SPRC
Clinical Trial2h ago
SciSparc Subsidiary NeuroThera Starts Phase IIb Trial Site for SCI-110
AcquisitionsJun 4, 7:33 AM
SciSparc Subsidiary NeuroThera Acquires 54% of CliniQuantum for CAD$9.46M
AcquisitionsMay 29, 7:46 AM
SciSparc Subsidiary NeuroThera Gets Conditional Approval for CliniQuantum Acquisition